ISFM and AAFP consensus guidelines. Long-term use of NSAIDs in cats

Journal of Feline Medicine and Surgery

Volumn 12, Issue 7, 2010, Pages 521-538

  Sparkes, Andrew H ^a   Heiene, Reidun ^b   Lascelles, B Duncan X ^c   Malik, Richard ^d   Sampietro, Llibertat Real ^e   Robertson, Sheilah ^f   Scherk, Margie ^g   Taylor, Polly ^h  

^a International Society of Feline Medicine   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Clinica Veterinaria Bendinat   (Spain)

^f University of Florida College of Veterinary Medicine   (United States)

^g CatsINK   (Canada)

^h TAYLOR MONROE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CHRONIC DISEASE; DRUG ADMINISTRATION; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; PAIN; PRACTICE GUIDELINE; UNITED STATES; CAT DISEASES; VETERINARY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAT DISEASES; CATS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; INTERNATIONAL AGENCIES; PAIN; SOCIETIES, MEDICAL; UNITED STATES;

FELIDAE;

EID: 77954120002     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2010.05.004     Document Type: Article

References (108)

1. Hellyer P., Rodan I., Brunt J., et al. AAHA/AAFP pain management guidelines for dogs and cats. J Feline Med Surg 2007, 9:466-480.
2. ACVA American College of Veterinary Anesthesiologists' position paper on the treatment of pain in animals. J Am Vet Med Assoc 1998, 213:628-630.
3. Mathews K. Pain assessment and general approach to management. Vet Clin North Am Small Anim Pract 2000, 30:729-755. v.
4. Slingsby L., Waterman-Pearson A.E. Postoperative analgesia in the cat after ovariohysterectomy by use of carprofen, ketoprofen, meloxicam or tolfenamic acid. J Small Anim Pract 2000, 41:447-450.
5. Carroll G., Howe L., Peterson K. Analgesic efficacy of preoperative administration of meloxicam or butorphanol in onychectomized cats. J Am Vet Med Assoc 2005, 226:913-919.
6. Taylor P., Robertson S., Dixon M. Evaluation of the use of thermal thresholds to investigate NSAID analgesia in a model of inflammatory pain in cats. J Feline Med Surg 2007, 9:313-318.
7. Benito-De-La-Vibora J., Lascelles B., Garcia-Fernandez P., et al. Efficacy of tolfenamic acid and meloxicam in the control of postoperative pain following ovariohysterectomy in the cat. Vet Anaesth Analg 2008, 35:501-510.
8. Lascelles B., Capner C., Waterman-Pearson A.E. Current British veterinary attitudes to perioperative analgesia for cats and small mammals. Vet Rec 1999, 145:601-604.
9. Hugonnard M., Leblond A., Keroack S., et al. Attitudes and concerns of French veterinarians towards pain and analgesia in dogs and cats. Vet Anaesth Analg 2004, 31:154-163.
10. Robertson S. Managing pain in feline patients. Vet Clin North Am Small Anim Pract 2008, 38:1267-1290.
11. Lascelles B., Robertson S. DJD-associated pain in cats: what can we do to promote patient comfort?. J Feline Med Surg 2010, 12:200-212.
12. Robertson S., Lascelles B. Long-term pain in cats: how much do we know about this important welfare issue?. J Feline Med Surg 2010, 12:188-199.
13. Gunew M., Menrath V., Marshall R. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg 2008, 10:235-241.
14. Gowan R. Retrospective analysis of the long-term use of meloxicam in aged cats with musculoskeletal disorders and the effect on renal function [abstract]. J Vet Intern Med 2009, 23:1347.
15. Lascelles B., Hansen B., Roe S., et al. Evaluation of client-specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis. J Vet Intern Med 2007, 21:410-416.
16. Lascelles B., Henderson A., Hackett I. Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. J Small Anim Pract 2001, 42:587-593.
17. Beale B. Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats. Vet Clin North Am Small Anim Pract 2004, 34:271-289.
18. Lascelles B. Feline degenerative joint disease. Vet Surg 2010, 39:2-13.
19. Allan G. Radiographic features of feline joint diseases. Vet Clin North Am Small Anim Pract 2000, 30:281-302.
20. Hardie E., Roe S., Martin F. Radiographic evidence of degenerative joint disease in geriatric cats: 100 cases (1994-1997). J Am Vet Med Assoc 2002, 220:628-632.
21. Clarke S., Bennett D. Feline osteoarthritis: a prospective study of 28 cases. J Small Anim Pract 2006, 47:439-445.
22. Clarke S., Mellor D., Clements D., et al. Prevalence of radiographic signs of degenerative joint disease in a hospital population of cats. Vet Rec 2005, 157:793-799.
23. Bennett D., Morton C. A study of owner observed behavioural and lifestyle changes in cats with musculoskeletal disease before and after analgesic therapy. J Feline Med Surg 2009, 11:997-1004.
24. Slingerland L, Hazewinkel H, Meij B, et al. Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats. Vet J. In press, 2010. doi:10.1016/j.tvjl.2009.12.014.
25. Beam S., Rassnick K., Moore A., et al. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet Pathol 2003, 40:496-500.
26. Dibernardi L., Dore M., Davis J., et al. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007, 76:245-250.
27. Hayes A., Scase T., Miller J., et al. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J Comp Pathol 2006, 135:93-99.
28. Hayes A., Adams V., Scase T., et al. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J Small Anim Pract 2007, 48:394-399.
29. Healey K., Dawson S., Burrow R., et al. Prevalence of feline chronic gingivo-stomatitis in first opinion veterinary practice. J Feline Med Surg 2007, 9:373-381.
30. Buffington C., Westropp J., Chew D., et al. Clinical evaluation of multimodal environmental modification (MEMO) in the management of cats with idiopathic cystitis. J Feline Med Surg 2006, 8:261-268.
31. Gerber B., Boretti F., Kley S., et al. Evaluation of clinical signs and causes of lower urinary tract disease in European cats. J Small Anim Pract 2005, 46:571-577.
32. Giuliano E. Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology. Vet Clin North Am Small Anim Pract 2004, 34:707-723.
33. Lees P., Giraudel J., Landoni M., et al. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther 2004, 27:491-502.
34. Lees P., Landoni M., Giraudel J., et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004, 27:479-490.
35. Warner T., Mitchell J. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004, 18:790-804.
36. Clark T. The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. Vet Clin North Am Small Anim Pract 2006, 36:1061-1085.
37. Maddison J. Cats and NSAIDs -; what are the issues?. Ir Vet J 2007, 60:174-178.
38. Papich M.G. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. Vet Clin North Am Small Anim Pract 2008, 38:1243-1266.
39. Crofford L. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997, 49(Suppl.):15-19.
40. Wallace J. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999, 107:11S-16S. discussion 16S-17S.
41. Ito S., Okuda-Ashitaka E., Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001, 41:299-332.
42. Wooten J., Blikslager A., Marks S., et al. Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs. Am J Vet Res 2009, 70:1243-1249.
43. Wooten J., Blikslager A., Ryan K., et al. Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. Am J Vet Res 2008, 69:457-464.
44. Claria J., Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 2005, 11:3431-3447.
45. Landolfi J., Terio K. Transitional cell carcinoma in fishing cats (Prionailurus viverrinus): pathology and expression of cyclooxygenase-1, -2, and p53. Vet Pathol 2006, 43:674-681.
46. Millanta F., Citi S., Della Santa D., et al. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006, 98:115-120.
47. Newman S., Mrkonjich L. Cyclooxygenase-2 expression in feline pancreatic adenocarcinomas. J Vet Diagn Invest 2006, 18:590-593.
48. Bergh M., Budsberg S. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005, 19:633-643.
49. Coruzzi G., Venturi N., Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 2007, 78:96-110.
50. Harris R.J. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.
51. Ellis G., Blake D. Why are non-steroidal anti-inflammatory drugs so variable in their efficacy? A description of ion trapping. Ann Rheum Dis 1993, 52:241-243.
52. Radi Z. Pathophysiology of cyclooxygenase inhibition in animal models. Toxicol Pathol 2009, 37:34-46.
53. Khan K., Venturini C., Bunch R., et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998, 26:612-620.
54. Sellers R., Senese P., Khan K. Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug Chem Toxicol 2004, 27:111-122.
55. Yabuki A., Endo Y., Fujiki M., et al. Expression of cyclooxygenase-2 and nitric oxide synthase-1 in kidneys of dogs and cats with renal failure 2007, Bulletin of the Faculty of Agriculture-Kagoshima University, Japan.
56. Lascelles B., Court M., Hardie E., et al. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anaesth Analg 2007, 34:228-250.
57. Bush T., Shlotzhauer T., Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med 1991, 155:39-42.
58. Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?. Drugs Aging 2005, 22:185-200.
59. Schoenfeld P., Kimmey M., Scheiman J., et al. Review article: no-steroidal anti-inflammatory drug-associated gastrointestinal complications - guidelines for prevention and treatment. Aliment Pharmacol Ther 1999, 13:1273-1285.
60. Dubois R., Melmed G., Henning J., et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004, 19:197-208.
61. Lascelles B., Mcfarland J., Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Vet Ther 2005, 6:237-251.
62. Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009, 29:481-496.
63. Tannenbaum H., Davis P., Russell A., et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. CMAJ 1996, 155:77-88.
64. Livingston A. Mechanism of action of nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract 2000, 30:773-781.
65. Thombre A. Oral delivery of medications to companion animals: palatability considerations. Adv Drug Deliv Rev 2004, 56:1399-1413.
66. Papich M. Drug compounding for veterinary patients. AAPS J 2005, 7:E281-E287.
67. Thoulon F., Narbe R., Johnston L., et al. Metabolism and excretion of oral meloxicam in the cat [abstract]. J Vet Intern Med 2009, 23:695.
68. Lher T., Narbe R., Jons O., et al. Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. J Vet Pharmacol Ther 2009, 33. 10.1111/j.1365-2885.2009.01134.x.
69. Giraudel J., King J., Jeunesse E., et al. Use of a pharmacokinetic/ pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther 2009, 32:18-30.
70. Taylor P., Lees P., Reynoldson J., et al. Pharmacodynamics and pharmacokinetics of flunixin in the cat: a preliminary study. Vet Rec 1991, 128:258.
71. Smolensky M., Peppas N. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev 2007, 59:828-851.
72. Zamprogno H, Hansen B, Bondell H, et al. Development of a questionnaire to assess degenerative joint disease associated-pain in cats: item generation and questionnaire format. Am J Vet Res., in press.
73. Lascelles B., Hansen B.D., Thomson A., et al. Evaluation of a digitally integrated accelerometer-based activity monitor for the measurement of activity in cats. Vet Anaesth Analg 2008, 35:173-183.
74. Goodman L., Brown S., Torres B., et al. Effects of meloxicam on plasma iohexol clearance as a marker of glomerular filtration rate in conscious healthy cats. Am J Vet Res 2009, 70:826-830.
75. Weir M. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002, 69(Suppl. 1):SI53-SI58.
76. Griffin M., Yared A., Ray W. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000, 151:488-496.
77. Laine L., White W., Rostom A., et al. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008, 38:165-187.
78. Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol 2008, 23:2159-2173.
79. Winkelmayer W., Waikar S., Mogun H., et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008, 121:1092-1098.
80. Juhlin T., Jonsson B., Hoglund P. Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. Eur J Heart Fail 2008, 10:892-898.
81. Lelorier J., Bombardier C., Burgess E., et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol 2002, 18:1301-1308.
82. Morlans M., Laporte J.R., Vidal X., et al. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990, 30:717-723.
83. Perneger T., Whelton P., Klag M. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 1994, 331:1675-1679.
84. Rexrode K., Buring J., Glynn R., et al. Analgesic use and renal function in men. JAMA 2001, 286:315-321.
85. Gooch K., Culleton B., Manns B., et al. NSAID use and progression of chronic kidney disease. Am J Med 2007, 120:280.e1-280.e7.
86. Baigent C., Landray M., Leaper C., et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005, 45:473-484.
87. Van Der Woude F.J., Heinemann L., Graf H., et al. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 2007, 8:15.
88. Mclaughlin R. Management of chronic osteoarthritic pain. Vet Clin North Am Small Anim Pract 2000, 30:933-949.
89. Fored C., Ejerblad E., Lindblad P., et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001, 345:1801-1808.
90. IRIS. International Renal Interest Society - Staging of CKD. Accessed May 2010. http://wwwiris-kidneycom/pdf/IRIS2009_Staging_CKDpdf.
91. Bulman-Fleming J.C., Turner T., Rosenberg M. Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms. J Feline Med Surg 2010, 12:262-268.
92. Goldstein R., Marks S., Kass P., et al. Gastrin concentrations in plasma of cats with chronic renal failure. J Am Vet Med Assoc 1998, 213:826-828.
93. Cariou M., Halfacree Z., Lee K., et al. Successful surgical management of spontaneous gastric perforations in three cats. J Feline Med Surg 2010, 12:36-41.
94. Jones C., Budsberg S. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000, 217:721-729.
95. Tomlinson J., Blikslager A. Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair. J Am Vet Med Assoc 2003, 222:946-951.
96. Antman E., Bennett J., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115:1634-1642.
97. Gluszko P., Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?. Pol Arch Med Wewn 2009, 119:231-235.
98. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008, 19:102-107.
99. Carroll G., Simonson S. Recent developments in nonsteroidal antiinflammatory drugs in cats. J Am Anim Hosp Assoc 2005, 41:347-354.
100. Aithal G.P., Day C. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007, 11:563-575.
101. Rubenstein J., Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004, 20:373-380.
102. O'Connor N., Dargan P., Jones A. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 2003, 96:787-791.
103. Macphail C., Lappin M., Meyer D., et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998, 212:1895-1901.
104. Verbeeck R. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008, 64:1147-1161.
105. Loboz K., Shenfield G. Drug combinations and impaired renal function - the 'triple whammy'. Br J Clin Pharmacol 2005, 59:239-243.
106. Lascelles B., Blikslager A., Fox S., et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 2005, 227:1112-1117.
107. Hampshire V., Doddy F., Post L., et al. Adverse drug event reports at the United States Food and Drug Administration Center for Veterinary Medicine. J Am Vet Med Assoc 2004, 225:533-536.
108. Kuehn NF. North American Companion Animal Formulary. North American Compendiums, Inc; 2008.